Historic FDA approval marks first nonopioid breakthrough since Clinton era
The Food and Drug Administration announced Thursday its approval of suzetrigine, the first new painkiller greenlit by the ...
verywellhealth1h
New FDA-Approved Painkiller Is a Safer Alternative to Opioids
The FDA has approved a new type of painkiller that doesn't come with the risks of addiction and overdose associated with opioids.
FDA approves new pain medicine as opioid alternative. What to know about Journavx
The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...
FDA Approves Painkiller Meant To Eliminate The Risk Of Opioid Addiction
WASHINGTON (AP) — Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and OxyContin ...
Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
BMO raises Vertex stock price target to $545 from $520
BMO Capital Markets increased its price target on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares, moving the ...
dermatologyadvisor7h
FDA Alert: Pulmonology Drug Approvals, Recalls, and Device Updates
FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.
FDA approves first new non-opioid painkiller in decades, and it's from a MA company.
The U.S. Food and Drug Administration approved a new non-opioid pain medication developed by the Massachusetts-based company ...
KTEN11h
5 things to know for Jan. 31: Plane collision, Confirmation hearings, Pain medicine, Japan sinkhole, FireAid benefit concerts
While America retains a gold standard for airline safety, there are stresses on the US air travel system that have been ...
Vertex Pharmaceuticals’ JOURNA VX: Navigating Market Challenges Despite Promising Financial Outlook
Needham analyst Joseph Stringer has maintained their neutral stance on VRTX stock, giving a Hold rating today.Invest with Confidence: Follow ...
Cautious Outlook on Vertex Pharmaceuticals Amid Journavx Approval and Pricing Concerns
Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence ...